Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TNKS | O95271 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | AHR | P35869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20420723 | 0.87 | ALDH1A1 (0.53) | TP53HPGDPOLBALDH1A1MAPT | |
| SCHEMBL20428398 | 0.83 | PRF1 (0.49) | TP53HPGDPOLBTNKSALDH1A1 | |
| SCHEMBL20420777 | 0.76 | CA9 (0.54) | TP53HPGDTNKSTDP1HTT | |
| SCHEMBL20420769 | 0.74 | GABRP (0.60) | TNKSALDH1A1KDM4ELMNAHTT | |
| SCHEMBL20420761 | 0.74 | MAOB (0.58) | TP53HPGDPOLBTNKSALDH1A1 | |
| SCHEMBL13049770 | 0.73 | TNKS (0.51) | TP53HPGDPOLBTNKSALDH1A1 | |
| SCHEMBL15842563 | 0.72 | KDM4E (0.59) | TP53HPGDPOLBTNKSALDH1A1 | |
| SCHEMBL3055510 | 0.72 | HPGD (0.66) | TP53HPGDPOLBALDH1A1MAPT | |
| SCHEMBL31358750 | 0.72 | POLB (0.69) | TP53HPGDPOLBALDH1A1MAPT | |
| SCHEMBL5209780 | 0.72 | HPGD (0.62) | TP53HPGDPOLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108349959-B | 4-substituted coumarin derivative and preparation method and application thereof | 成都赜灵生物医药科技有限公司 | 2021-11-16 | — | — | CN | disclosed |
| US-10544134-B2 | 4-substituted coumarin derivatives and preparation methods and uses thereof | GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. (CN) | 2020-01-28 | — | — | US | disclosed |
| US-20180282315-A1 | 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF | CHENGDU ZENITAR BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2018-10-04 | — | — | US | disclosed |
| EP-3354648-A1 | 4-SUBSTITUED COUMARIN DERIVATIVE, AND PREPARATION METHOD AND USE THEREOF | Guizhou Bailing Group Pharmaceutical Co., Ltd. (CN) | 2018-08-01 | — | — | EP | disclosed |
| CN-108349959-A | The coumarin derivative and its preparation method and application of 4 substitutions | 贵州百灵企业集团制药股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544134-B2 | 4-substituted coumarin derivatives and preparation methods and uses thereof | MAP4, TUBA3C, ABCC1 | TP53 714/4885HPGD 2933/4885POLB 3352/4885 |
| US-20180282315-A1 | 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF | MAP4, TUBA3C, ABCC1 | TP53 714/4885HPGD 2933/4885POLB 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.